Clinical Trial: MSC for Occlusive Disease of the Kidney
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis
Brief Summary: To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.
Detailed Summary: Individuals with unilateral arterial occlusive disease will be treated to injured kidney with autologous cells.
Sponsor: Mayo Clinic
Current Primary Outcome: Renal blood flow and function in the treated kidneys. [ Time Frame: 2 years ]
Original Primary Outcome: Renal blood flow and function in the treated kidneys. [ Time Frame: 2 years ]
Current Secondary Outcome: Level of kidney function. [ Time Frame: 2 years ]
Original Secondary Outcome: Level of kidney function and blood pressure. [ Time Frame: 2 years ]
Information By: Mayo Clinic
Dates:
Date Received: April 23, 2013
Date Started: April 2013
Date Completion: April 2017
Last Updated: October 8, 2015
Last Verified: October 2015